Prevalence of the human papillomavirus (HPV) types among cervical dysplasia women attending a gynaecological clinic in Sweden.

García FR, Norenhag J, Edfeldt G, Cheng L, Hugerth LW, Pennhag AAL, Schuppe-Koistinen I, Engstrand L, Olovsson M, Du J

BJC Rep 1 (1) 11 [2023-08-22; online 2023-08-22]

Human papillomavirus (HPV) is the main cause of cervical cancer. HPV-vaccines have led to a significant decrease in HPV-infections and related cancer cases. The estimation of the current HPV-prevalence and distribution of different HPV-types among women with cervical dysplasia is important for the future vaccination strategy. By using a multiplexed bead-based immunoassay, we revealed the prevalence of 27 HPV-types in 168 dysplasia women aged 21-70 from Uppsala University hospital, Sweden. The prevalence of HPV in low-and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively) were 56.3% and 76.7%, respectively. The oncogenic HPV-types constituted 80.0%, and 97.1% among the HPV-positive LSIL and HSIL-groups, respectively, with HPV16 as the most prevalent type. We found a reduction in oncogenic HPV-types covered by the bi- and quadrivalent vaccines in the vaccinated HSIL-group, suggesting the effectiveness of the HPV-vaccine in preventing dysplasia caused by the covered HPV-types. Oncogenic HPV-types 39 and 59, not covered by any current vaccine have an important prevalence among patients with cervical dysplasia. Oncogenic-HPV-types are highly prevalent among women with HSIL. The current vaccine presents effectiveness for reducing the covered HPV-types among dysplasia patients.

PubMed 39516656

DOI 10.1038/s44276-023-00012-y

Crossref 10.1038/s44276-023-00012-y

pmc: PMC11524002
pii: 10.1038/s44276-023-00012-y